LB Pharmaceuticals Inc. (LBRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain receptor occupancy at much lower doses than amisulpride, supporting once-daily dosing and potentially fewer side effects. The main investment debate centers on whether the R-enantiomer's 5-HT7 activity delivers unique clinical benefits beyond D2/D3 antagonism, which remains unproven.
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 200,000 | $3.16M | $7.32M | $4.16M | 131.81% |
| CD Charlie Durham Sterling Capital Management LLC | 274 | $6,099.28 | $9,316 | $3,216.72 | 52.74% |
| NM Nir Messafi Deep Track Capita LLP | 3.35M | $52.94M | $121.04M | $68.1M | 128.63% |
 Joseph Castro Nuveen LLC | 52,142 | $1.46M | $1.77M | $314,697.7 | 21.58% |
 Drew Phillips Fortitude Family Office LLC | 10 | $384 | $366.9 | -$17.1 | -4.45% |
LB Pharmaceuticals Inc. (LBRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LB Pharmaceuticals Inc. ever had a stock split?
LB Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Heather D. Turner CEO | NASDAQ (NMS) Exchange | 50180M108 CUSIP |
| US Country | 49 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
This clinical-stage biopharmaceutical company is dedicated to the innovation and development of novel therapies aimed at treating neuropsychiatric diseases, which include disorders such as schizophrenia and bipolar depression. As a pioneer in the field, the company is committed to addressing the unmet needs of patients suffering from these conditions by leveraging cutting-edge research and drug development methodologies. Its rigorous clinical trials are focused on creating effective and safe treatment options that can significantly improve the quality of life for those affected by such challenging mental health issues.
Products and Services
- LB‑102: A lead candidate therapy, LB-102 is a methylated derivative of amisulpride, specifically designed to offer enhanced therapeutic benefits for individuals suffering from neuropsychiatric disorders. The drug's formulation aims to improve efficacy while minimizing side effects typically associated with traditional treatments.
Contact Information
